These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

412 related items for PubMed ID: 12244484

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Absolute and comparative subcutaneous bioavailability of ardeparin sodium, a low molecular weight heparin.
    Troy S, Fruncillo R, Ozawa T, Mammen E, Holloway S, Chiang S.
    Thromb Haemost; 1997 Aug; 78(2):871-5. PubMed ID: 9268187
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
    Maddineni J, Walenga JM, Jeske WP, Hoppensteadt DA, Fareed J, Wahi R, Bick RL.
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
    [Abstract] [Full Text] [Related]

  • 28. Comparison of the pharmacodynamic and pharmacokinetic profiles of two low-molecular-mass heparins in rats.
    Piazolo L, Harenberg J, Malsch R, Hüttner FG, Heene DL.
    Semin Thromb Hemost; 1997 Jul; 23(2):109-17. PubMed ID: 9200334
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin.
    Mischke R, Grebe S.
    Res Vet Sci; 2000 Dec; 69(3):241-7. PubMed ID: 11124095
    [Abstract] [Full Text] [Related]

  • 33. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin.
    Young E, Wells P, Holloway S, Weitz J, Hirsh J.
    Thromb Haemost; 1994 Mar; 71(3):300-4. PubMed ID: 8029793
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Pharmacokinetics of UH and LMWH are similar with respect to antithrombin activity.
    Morris TA, Jacobson A, Marsh JJ, Lane JR.
    Thromb Res; 2005 Mar; 115(1-2):45-51. PubMed ID: 15567452
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Low molecular weight heparins prevent thrombin-induced thrombo-embolism in mice despite low anti-thrombin activity. Evidence that the inhibition of feed-back activation of thrombin generation confers safety advantages over direct thrombin inhibition.
    Momi S, Nasimi M, Colucci M, Nenci GG, Gresele P.
    Haematologica; 2001 Mar; 86(3):297-302. PubMed ID: 11255277
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.